CYP3A5 Gene

2020 ◽  
Author(s):  
Keyword(s):  
Cyp3a5 Gene

scholarly journals No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

2018 ◽  
Vol 59 (1) ◽  
pp. 139-152
Author(s):  
Manoli Vourvahis ◽  
Lynn McFadyen ◽  
Sunil Nepal ◽  
Srinivas Rao Valluri ◽  
Annie Fang ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Gene Polymorphisms ◽  
Clinical Impact ◽  
Cyp3a5 Gene ◽  
Hiv 1

scholarly journals CYP4F2 and CYP3A5 gene polymorphisms and lung cancer in Chinese Han population

2020 ◽  
Vol 20 (3) ◽  
pp. 461-468
Author(s):  
Ruiqing He ◽  
Meng Li ◽  
Anqi Li ◽  
Wenhui Dang ◽  
Tian Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Polymorphisms ◽  
Chinese Han Population ◽  
Chinese Han ◽  
Han Population ◽  
Cyp3a5 Gene

Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism

2013 ◽  
Vol 14 (9) ◽  
pp. 1017-1025 ◽  
Author(s):  
Philippe Durand ◽  
Dominique Debray ◽  
Mikaela Kolaci ◽  
Jerome Bouligand ◽  
Valérie Furlan ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Gene Polymorphism ◽  
Pediatric Liver Transplantation ◽  
Dose Requirement ◽  
Pediatric Liver ◽  
Cyp3a5 Gene ◽  
Tacrolimus Dose

scholarly journals CYP3A5 Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition

2013 ◽  
Vol 95 (6) ◽  
pp. 821-827 ◽  
Author(s):  
Songmao Zheng ◽  
Yasar Tasnif ◽  
Mary F. Hebert ◽  
Connie L. Davis ◽  
Yoshihisa Shitara ◽  
...  
Keyword(s):  
Cyclosporine A ◽  
Metabolite Formation ◽  
Gene Variation ◽  
Cyp3a5 Gene

scholarly journals Examination of CYP3A5 gene polymorphisms was useful for adjusting doses of tacrolimus in outpatients with rheumatic diseases

2018 ◽  
Vol WCP2018 (0) ◽  
pp. PO3-14-7
Author(s):  
Shinji Horibata ◽  
Miho Takahashi ◽  
Kennosuke Yorihuji ◽  
Miwa Nishida ◽  
Goh Tuji ◽  
...  
Keyword(s):  
Rheumatic Diseases ◽  
Gene Polymorphisms ◽  
Cyp3a5 Gene

scholarly journals Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern India

2020 ◽  
Vol 5 (1) ◽  
pp. 28-38 ◽  
Author(s):  
Narayan Prasad ◽  
Akhilesh Jaiswal ◽  
Manas Ranjan Behera ◽  
Vikas Agarwal ◽  
Ravi Kushwaha ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Gene Polymorphism ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Northern India ◽  
Cyp3a5 Gene

scholarly journals CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

2020 ◽  
Vol 11 ◽  
Author(s):  
Effrosyni Mendrinou ◽  
Mohamed Elsayed Mashaly ◽  
Amir Mohamed Al Okily ◽  
Mohamed Elsayed Mohamed ◽  
Ayman Fathi Refaie ◽  
...  
Keyword(s):  
Living Donor ◽  
Cyp3a5 Gene

scholarly journals Donor CYP3A5 Gene Polymorphism Alone Cannot Predict Tacrolimus Intrarenal Concentration in Renal Transplant Recipients

2020 ◽  
Vol 21 (8) ◽  
pp. 2976
Author(s):  
Mengyu Zhang ◽  
Soichiro Tajima ◽  
Tomohiro Shigematsu ◽  
Rao Fu ◽  
Hiroshi Noguchi ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Gene Polymorphism ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Renal Metabolism ◽  
Renal Tubular Cells ◽  
Transplant Patients ◽  
Graft Outcome ◽  
Cyp3a5 Gene

CYP3A5 gene polymorphism in recipients plays an important role in tacrolimus blood pharmacokinetics after renal transplantation. Even though CYP3A5 protein is expressed in renal tubular cells, little is known about the influence on the tacrolimus intrarenal exposure and hence graft outcome. The aim of our study was to investigate how the tacrolimus intrarenal concentration (Ctissue) could be predicted based on donor CYP3A5 gene polymorphism in renal transplant recipients. A total of 52 Japanese renal transplant patients receiving tacrolimus were enrolled in this study. Seventy-four renal biopsy specimens were obtained at 3 months and 1 year after transplantation to determine the donor CYP3A5 polymorphism and measure the Ctissue by liquid chromatography-tandem mass spectrometry (LC-MS-MS). The tacrolimus Ctissue ranged from 52 to 399 pg/mg tissue (n = 74) and was weak but significantly correlated with tacrolimus trough concentration (C0) at 3 months after transplantation (Spearman, r = 0.3560, p = 0.0096). No significant relationship was observed between the donor CYP3A5 gene polymorphism and Ctissue or Ctissue/C0. These data showed that the tacrolimus systemic level has an impact on tacrolimus renal accumulation after renal transplantation. However, donor CYP3A5 gene polymorphism alone cannot be used to predict tacrolimus intrarenal exposure. This study may be valuable for exploring tacrolimus renal metabolism and toxicology mechanism in renal transplant recipients.

Sign in / Sign up

Export Citation Format

Share Document